Evidera: Market Access Consulting Services

With rigorous, evolving, and heterogeneous payer evaluation criteria, challenging price negotiations, and a dynamic competitive environment, manufacturers need to prepare their market access strategy early in the product life cycle and assess often to ensure optimal access. Evidera is ideally positioned to help you create evidence-optimized value strategies to achieve your product access, price and reimbursement goals. Our team brings …

Doug Monroe of Kaiser Permanente's 2015 Presentation

Kaiser Permanente: the impact of biosimilars on private reimbursement

We were excited to have Doug Monroe, Project Manager of Biotechnology, Emerging Technology, and Specialty Pharmacy at Kaiser Permanente, share his expertise on the impact of biosimilars on private reimbursement strategies at the World Biosimilar Congress USA. Download his presentation now > You can now download Doug’s presentation to find out more about: The Kaiser Permanente integrated health care delivery system …

“Planning for Reimbursement Success in Clinical Development”

Sven Kili of Sanofi Biosurgery joined us for Stem Cells & Regenerative Medicine Congress USA 2014 to present about ‘ Planning for Reimbursement Success in Clinical Development’.   Download his presentation now to understand more about: Focusing on value in planning and carrying out a clinical development plan Mechanisms to develop a value message Key opinion leader management and reimbursement planning Launch activities–focusing …

The Netherlands: In the midst of change

  At the World Pharma Pricing & Market Access Congress 2014 conference, Dr Martin van der Graaff, Secretary, Reimbursement Committee, CVZ gave the presentation: “The Netherlands: In the mi(d)st of change” Download and learn: Organisational change in CVZ End of an era: Policy rules and outcomes research First results and experiences with CED Preliminary criteria for prioritizing inpatient drugs Priorities Are …

Download ebook: Top Market Access Services Required by BioPharma

Pharmaceutical market access is not easy. It can seem fickle, lengthy and very complicated. Ensuring that your medicines get to the patients that need them involves dealing with clinicians, payers, HTA bodies and internal and external stakeholders. Just as you think you understand the rules of the game, they change. Value based pricing anyone? It is perhaps no surprise that …

“There are so many people in India that even patients with rare diseases can be found in sufficient numbers to conduct good scientific research”

Michael Hauser, a Duke professor of medicine and ophthalmology, who collaborates with an eye institute in Hyderabad, India to study a childhood form of glaucoma, was quoted in a recent article published on the Duke website about how Global Research can harness Domestic benefits. To prove his point, it was also mentioned that Hauser’s team in Durham were able to identify 75 patients with …

Download ebook: Why clinical trials fail and what we can do about it

    The challenges that the pharmaceutical industry faces in launching a drug are plentiful and well documented. From the cost of R&D, high failure rate, ever toughening reimbursement requirements and ever growing competition. One significant element of getting a product approved is a successful clinical trials. It is an exciting time for the industry as there are signs of …

Download: Risk Based Pricing in Healthcare: current practice and future prospects

  Last year's Pharma Pricing & Market Access Europe 2013, key topics discussed included maneuvering changes in the healthcare environment, pricing & market access in the major international markets and patient access and flexible pricing schemes. At last year’s event, a notable presentation was given by Allen King, Global Pricing Leader at Optum, entitled on risk based pricing in healthcare: …

Download: Adapting Market Access to New Challenges in Oncology

  At Pharma Pricing & Market Access Europe 2013, key people in the field of pharma marketing discussing topics from maneuvering changes in the healthcare environment to pricing & market access in the major international markets and patient access and flexible pricing schemes. Among the many other speeches and discussions, Ipsen’s SVP Market Access & Pricing, Sylvie Gabriel’s presentation entitled …

Download ebook: Top tips and takeaways from Pharma Pricing & Market Access Outlook 2013

We have put together the top 10 slides from our Pharma Pricing & Market Access Outlook Europe 2013 presentations. All of these slides were part of in-depth, informative presentations given by industry professionals, addressing the critical policy issues in developing the optimum pricing strategy for pharmaceutical products. Some top presentation topics included: Three vital areas for improving market access Scarcity,value …